Overview

This trial has been completed.

Condition lung cancer
Sponsor iOMEDICO AG
Start date January 2010
End date July 2016
Trial size 2500 participants
Trial identifier NCT01192919, IOM TLK

Summary

Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Patients with lung cancer requiring therapy

Primary Outcomes

Measure
Documentation of actually used therapy forms in bronchial carcinoma requiring treatment
time frame: 3 years per patient

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy - written informed consent - start of neoadjuvant, adjuvant or first-line therapy no longer than 4 weeks before informed consent Exclusion Criteria: - patients not receiving any systemic therapy

Additional Information

Official title Clinical Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy.
Principal investigator Hans-Werner Tessen, MD
Description The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by iOMEDICO AG.